ASMB ASSEMBLY BIOSCIENCES, INC.

Price Chart

Executive Summary

Assembly Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders approved an increase in shares reserved under the 2018 Stock Incentive Plan from 1,478,333 to 2,678,333 (a 1,200,000-share increase) and an increase in the Employee Stock Purchase Plan from 225,000 to 515,000 shares. All nine director nominees were elected, and the appointment of Ernst & Young as auditor was ratified. This is a routine governance filing with no material financial impact.

Actionable Insight

Key Facts

• Stockholders approved Amendment No. 3 to the 2018 Stock Incentive Plan, increasing authorized shares from 1,478,333 to 2,678,333.
• Stockholders approved Amendment No. 2 to the ESPP, increasing reserved shares from 225,000 to 515,000.
• All nine director nominees were elected with overwhelming support (over 99% of votes cast for each).
• Ernst & Young LLP was ratified as independent auditor for fiscal 2026.
• Say-on-pay proposal passed with approximately 99.8% of votes cast in favor.

Financial Impact

No financial figures reported. The share reserve increases enable future equity compensation but no shares were issued in this filing.

Risk Factors

• Potential future dilution from the 1,200,000 additional shares authorized under the stock incentive plan.
• No operational or financial updates provided in this filing.

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status